RESEARCH OF THE EFFECTIVENESS OF THE MULTIFUNCTION-
AL PEPTIDE PREPARATION REVILAB ML 09 IN STAGE 2 COXAR-
THROSIS
Study period — April 2016 – November 2018
Location — Russia, Moscow, Moscow office of the Peptides
Research and Production Center of Revitalization and Health
Actual enrolment — 51 participants
Age — 58–66 y.o.
Dosage regimen — 1 capsule in the morning a. c. daily
Period of administration — 4 months
RESEARCH RESULTS OF THE EFFECTIVENESS OF REVILAB ML 09
IN STAGE 2 COXARTHROSIS
Parameter Placebo Placebo ML 09 ML 09 group
group before group after group before after treatment,
treatment, treatment, treatment,
29 participants 29 participants 22 participants 22 participants
Pain and 26 (89%) 26 (89%) 19 (86%) 6* (27%)
discomfort
Limitation of 18 (62%) 17 (59%) 18 (82%) 7* (32%)
motion
Improvement ― None ― 16* (73%)
in infrared
thermography
Improvement ― None ― 14* (64%)
in X-ray and
computed
tomography
*Accurate changes in comparison with the placebo group.
114 // Health territory. PEPTIDES. A Few Words on Joints
Для таблиц, дозировок и примечаний сверяйтесь с оригинальным PDF: при извлечении текста порядок колонок может измениться.
Из библиотеки Peptides. Авторство и содержание оригинала сохранены. Размещено с разрешения поставщика.